ESMO

Therapies for Some With Prostate Cancer Focuses on Reducing Side Effects

September 16th 2024, 3:00pm

Video

At the 2024 ESMO Congress, an expert explained how Nubeqa may reduce fatigue-related side effects in metastatic hormone-sensitive prostate cancer.

Imfinzi Continuously Demonstrates Survival Benefit in Limited Stage SCLC

September 16th 2024, 1:00pm

Article

Patients with limited-stage small cell lung cancer saw improvements in progression-free survival and overall survival with Imfinzi versus placebo.

Perioperative Imfinzi, Neoadjuvant Chemo Improves Survival in Muscle-Invasive Bladder Cancer

September 15th 2024, 10:19pm

Article

Imfinzi and chemotherapy before surgery, followed by Imfinzi after surgery, generated survival benefits in cisplatin-eligible muscle-invasive bladder cancer.

Enhertu Maintains Quality of Life in Metastatic Breast Cancer Subgroup

September 15th 2024, 8:39pm

Article

Enhertu also improved the time to deterioration for pain and other factors in patients with HR-positive, HER2-low and -ultralow metastatic breast cancer.

Cyramza Plus Lonsurf Did Not Improve Survival in Metastatic Colorectal Cancer

September 15th 2024, 8:00pm

Article

Treatment with Cyramza plus Lonsurf did not improve overall survival compared with Lonsurf alone in heavily pretreated metastatic colorectal cancer.

Chemotherapy De-Escalation Associated With Excellent HR+/HER2+ Breast Cancer Survival

September 15th 2024, 7:30pm

Article

Patients with early breast cancer treated with presurgical endocrine therapy or chemotherapy plus Herceptin and Perjeta followed by response-guided chemotherapy experienced “exceptionally excellent” survival outcomes.

Outcomes, Lymphedema Risk May Be Similar With Hypofractionated Versus Normofractionated Radiation in Early Breast Cancer

September 15th 2024, 7:00pm

Article

Hypofractionated radiation was noninferior to normofractionated radiation in patients with early breast cancer regarding lymphedema risk.

Presurgical Keytruda-Chemo Combo With Postsurgical Keytruda May Improve Survival in Early TNBC

September 15th 2024, 6:25pm

Article

Patients with early triple-negative breast cancer had improved survival outcomes after receiving presurgical Keytruda plus chemotherapy and postsurgical Keytruda.

Antibody-Drug Conjugate Is Tolerable, Active in CLDN6-Positive Solid Tumors Including Ovarian Cancer

September 15th 2024, 5:52pm

Article

Treatment with the antibody-drug conjugate TORL-1-23 was safe and tolerable in heavily pretreated, CLDN6-positive advanced solid tumors, including platinum-resistant ovarian cancer.

Zynyz Plus Chemo Combo Improves Survival in Recurrent/Metastatic SCAC

September 14th 2024, 11:00pm

Article

Adding Zynyz to carboplatin and paclitaxel prolonged survival without progression in chemotherapy-naive recurrent or metastatic squamous cell carcinoma of the anal canal.